Author

Tejas Patil

Institutions: University of Colorado Cancer Center, University of Colorado Anschutz

Observed institutions: University of Colorado Cancer Center, University of Colorado Anschutz

ORCID: 0000-0003-4389-1010

Observed ORCID: 0000-0003-4389-1010

OpenAlex ID: A5120946535

NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026

2026 · Apar Kishor P. Ganti, Billy W. Loo, et al. · Journal of the National Comprehensive Cancer Network · 7

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( NRG1 ) Fusions

2025 · Tejas Patil, Jessica J. Lin, et al. · JCO Precision Oncology · 5

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium

2026 · Sarah Waliany, Alissa J. Cooper, et al. · Clinical Cancer Research · 4

Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025

2026 · Narjust Florez, Sandip Pravin Patel, et al. · Cancer

Abstract 5252: Computational modeling of comprehensive genomic profiling to predict chemo-immunotherapy benefit in early stage NSCLC

2026 · Prashant Nair, Kishor Promod, et al. · Cancer Research

Abstract 2449: Comparison of liquid versus solid tissue genomic profiling for the prediction of chemo-immunotherapy benefit in advanced NSCLC

2026 · Charu Aggarwal, Prashant Nair, et al. · Cancer Research

Works count: 6

Citation count: 16

H-index: 3

I10-index: